Vistagen Therapeutics, Inc.
VTGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001411685
No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Vistagen Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 101 | 3 | 105 | +7 |
| Shares | 123.5M | 256.4K | 131.4M | +8.21M (+6.7%) |
| Value | $389.0M | $809.0K | $360.2M | −$27.9M (−7.2%) |
3 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| EAM Global Investors LLC | 634,743 | $1.74M | 0.41% |
| Rafferty Asset Management, LLC | 246,683 | $676.0K | 0.00% |
| Twin Lakes Capital Management, LLC | 94,500 | $259.0K | 0.15% |
| Occudo Quantitative Strategies LP | 94,009 | $258.0K | 0.03% |
| Bulltick Wealth Management, LLC | 89,840 | $246.2K | 0.06% |
| Wells Fargo & Company | 85,954 | $235.0K | 0.00% |
| SG Americas Securities, LLC | 75,925 | $208.0K | 0.00% |
| Gsa Capital Partners LLP | 31,984 | $88.0K | 0.01% |
| Financial Advocates Investment Management | 23,097 | $63.0K | 0.00% |
| Dorsey & Whitney Trust CO LLC | 20,000 | $55.0K | 0.01% |
| Genesee Capital Advisors, LLC | 19,860 | $54.0K | 0.03% |
| E Fund Management Co., Ltd. | 13,783 | $38.0K | 0.00% |
| Zacks Investment Management | 12,000 | $33.0K | 0.00% |
| Mackenzie Financial Corp | 11,230 | $31.0K | 0.00% |
| Russell Investments Group, Ltd. | 8,317 | $22.0K | 0.00% |
| Koshinski Asset Management, Inc. | 3,600 | $9.86K | 0.00% |
| Spire Wealth Management | 600 | $2.00K | 0.00% |
| Gerber Kawasaki Wealth & Investment Management | 144 | $0 | 0.00% |
Sold out (11)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Jane Street Group, LLC | 165,645 | $521.0K |
| Monashee Investment Management LLC | 157,000 | $495.0K |
| Renaissance Technologies LLC | 102,641 | $323.0K |
| ACT Capital Management, LLC | 100,000 | $315.0K |
| STRS Ohio | 44,300 | $139.0K |
| Quantitative Systematic Strategies LLC | 29,289 | $92.0K |
| Blair William & Co | 12,200 | $38.0K |
| Xponance, Inc. | 10,473 | $33.0K |
| Paradigm, Strategies in Wealth Management, LLC | 1,000 | $3.00K |
| Atticus Wealth Management, LLC | 692 | $2.00K |
| Advisory Services Network, LLC | 80 | $0 |
Not filed for Q3 2021 yet (3)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| QS Investors, LLC | 177,900 | $561.0K |
| M Holdings Securities, Inc. | 65,000 | $205.0K |
| CWM, LLC | 13,500 | $43.0K |